alpha-synuclein pathology: dangerous mitochondrial interactions
Published 3 years ago • 315 plays • Length 1:57Download video MP4
Download video MP3
Similar videos
-
2:05
alpha-synuclein inhibitors, kinase inhibitors & targeting mitochondria in parkinson’s disease
-
1:34
is α-synuclein aggregation a cause or consequence of parkinson’s disease?
-
1:53
mitochondrial dysfunction is hallmark of early sporadic pd
-
4:00
peripheral α-synuclein as a parkinson’s disease biomarker
-
1:46
therapeutic approaches to target alpha-synuclein in parkinson’s disease
-
3:34
the role of an alpha-synuclein protein in the human body
-
2:50
insights into parkinson’s disease pathology: α-syn & phosphoinositides
-
1:21
investigating α-synuclein aggregation as a therapeutic target in parkinson’s disease
-
6:26
protein aggregation with the focus on alpha-synuclein
-
50:24
#15 - parkinson's disease & mitochondrial dysfunction | andy lee, coo vincere biosciences
-
59:06
creating new neurons: the potential to reverse parkinson’s disease
-
2:02
glycation of α-synuclein in parkinson’s disease
-
4:31
is α-synuclein a useful therapeutic target in parkinson's disease?
-
1:17
impact of α-synuclein on synaptic function
-
2:43
doxycycline inhibits alpha-synuclein aggregation in pd models
-
2:26
alpha-synuclein as a therapeutic target for parkinson's disease
-
3:06
quantifying cutaneous alpha-synuclein to diagnose and differentiate synucleinopathies
-
3:07
α-synuclein conformation as a novel blood biomarker in parkinson’s disease
-
1:26
targeting α-synuclein & neuroinflammation in parkinson's disease
-
2:19
advances in alpha-synuclein as a biomarker for parkinson's disease
-
3:32
parkinson’s disease : alpha-synuclein, a major factor ?
-
1:52
epigenomic and epitranscriptomic effects of α-synuclein in the nucleus